Ebola Fever Therapeutic Market is driven by increasing investments in drug R&D

Ebola fever, also known as Ebola hemorrhagic fever (EHF), is a rare and deadly disease caused by infection with one of the Ebola virus strains. Symptoms include fever, headache, joint and muscle aches, sore throat, and weakness, followed by diarrhea, vomiting, and stomach pain. In some cases, internal and external bleeding may occur. The Ebola virus disease (EVD) outbreak in West Africa from 2014 to 2016 caused significant mortality and highlighted the need for effective therapeutics and vaccines. The primary treatment for Ebola virus disease is supportive care, such as maintaining optimal fluid and electrolyte balance and blood pressure levels. However, several vaccines and drug therapies are currently under clinical trials.

The Ebola fever therapeutic market is estimated to be valued at USD 0.742 bn in 2024 and is expected to reach USD 1.116 bn by 2031, growing at a compound annual growth rate (CAGR) of 6% from 2024 to 2031.


Ebola Fever Therapeutic Market-https://www.coherentmi.com/ind....ustry-reports/ebola-

Explore More Related Articles – https://www.coherentmi.com/blo....g/the-growing-viral-